Swiss National Bank Boosts Holdings in 10x Genomics, Inc. (NASDAQ:TXG)

Swiss National Bank boosted its holdings in shares of 10x Genomics, Inc. (NASDAQ:TXG) by 1.5% in the 4th quarter, HoldingsChannel.com reports. The institutional investor owned 188,400 shares of the company’s stock after buying an additional 2,700 shares during the quarter. Swiss National Bank’s holdings in 10x Genomics were worth $2,705,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds and other institutional investors have also added to or reduced their stakes in the company. Atria Wealth Solutions Inc. increased its holdings in 10x Genomics by 9.6% in the 4th quarter. Atria Wealth Solutions Inc. now owns 10,788 shares of the company’s stock worth $155,000 after acquiring an additional 943 shares in the last quarter. Blue Trust Inc. lifted its holdings in 10x Genomics by 73.1% during the fourth quarter. Blue Trust Inc. now owns 3,075 shares of the company’s stock valued at $44,000 after purchasing an additional 1,299 shares in the last quarter. Sound Income Strategies LLC boosted its position in shares of 10x Genomics by 65.2% in the fourth quarter. Sound Income Strategies LLC now owns 3,370 shares of the company’s stock worth $48,000 after purchasing an additional 1,330 shares during the period. KBC Group NV increased its stake in shares of 10x Genomics by 57.3% in the fourth quarter. KBC Group NV now owns 5,072 shares of the company’s stock worth $73,000 after purchasing an additional 1,847 shares in the last quarter. Finally, Commerce Bank raised its position in shares of 10x Genomics by 17.1% during the 3rd quarter. Commerce Bank now owns 13,296 shares of the company’s stock valued at $300,000 after purchasing an additional 1,946 shares during the period. 84.68% of the stock is owned by hedge funds and other institutional investors.

10x Genomics Trading Down 1.8 %

Shares of NASDAQ:TXG opened at $9.41 on Friday. The company has a market cap of $1.15 billion, a price-to-earnings ratio of -6.19 and a beta of 1.93. 10x Genomics, Inc. has a 12 month low of $9.27 and a 12 month high of $38.49. The company has a 50-day moving average price of $12.24 and a 200 day moving average price of $15.22.

10x Genomics (NASDAQ:TXG) last posted its quarterly earnings data on Wednesday, February 12th. The company reported ($0.40) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.32) by ($0.08). 10x Genomics had a negative net margin of 29.90% and a negative return on equity of 25.40%. As a group, equities analysts forecast that 10x Genomics, Inc. will post -1.43 EPS for the current year.

Analysts Set New Price Targets

Several research analysts recently weighed in on TXG shares. Leerink Partners downgraded shares of 10x Genomics from an “outperform” rating to a “market perform” rating and dropped their target price for the stock from $25.00 to $12.00 in a report on Thursday, February 13th. Weiss Ratings restated a “sell (e+)” rating on shares of 10x Genomics in a research report on Saturday, March 22nd. Canaccord Genuity Group cut their target price on 10x Genomics from $20.00 to $18.00 and set a “buy” rating for the company in a research report on Thursday, February 13th. Barclays lowered their price target on 10x Genomics from $19.00 to $18.00 and set an “overweight” rating on the stock in a report on Monday, February 10th. Finally, Stifel Nicolaus dropped their price target on 10x Genomics from $21.00 to $18.00 and set a “buy” rating for the company in a research note on Thursday, February 13th. One research analyst has rated the stock with a sell rating, nine have assigned a hold rating and seven have given a buy rating to the company’s stock. According to data from MarketBeat.com, 10x Genomics presently has an average rating of “Hold” and an average price target of $20.21.

Insiders Place Their Bets

In other news, CEO Serge Saxonov sold 5,092 shares of the business’s stock in a transaction on Monday, February 24th. The shares were sold at an average price of $11.07, for a total transaction of $56,368.44. Following the completion of the sale, the chief executive officer now directly owns 879,482 shares of the company’s stock, valued at approximately $9,735,865.74. The trade was a 0.58 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, insider Benjamin J. Hindson sold 4,573 shares of the firm’s stock in a transaction dated Monday, February 24th. The stock was sold at an average price of $11.07, for a total transaction of $50,623.11. Following the completion of the transaction, the insider now directly owns 335,324 shares in the company, valued at $3,712,036.68. This represents a 1.35 % decrease in their position. The disclosure for this sale can be found here. 10.03% of the stock is owned by insiders.

10x Genomics Company Profile

10x Genomics, Inc, a life science technology company, develops and sells instruments, consumables, and software for analyzing biological systems in the America, Europe, the Middle East, Africa, China, and the Asia Pacific. The company provides chromium, chromium connect, and chromium controller instruments, microfluidic chips, slides, reagents, and other consumables products.